1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
AddLife AB (publ)

AddLife AB (publ)

ADDLF
AddLife AB (publ)US flagOther OTC
15.75
USD
- -
- -
1.85BMarket Cap
AddLife AB (publ)
ADDLF
(Other OTC)

Recent

price

15.75

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
9.94
10.78
13.64
19.83
22.83
24.7
31.32
47.03
66.93
74.59
79.48
84.41
85.69
85.69
Revenue per Share
0.81
0.86
1.04
0.99
1.18
1.29
1.27
4.62
6.02
3.94
1.56
2.07
4.6
2.77
Basic EPS, GAAP
1.2
0.86
1.34
0.96
1.62
1.28
2.83
7.65
7.26
5.15
3.82
6.55
9.09
9.54
Free Cash Flow per Basic Share
1.01
1.06
1.03
3.74
0.36
0.53
0.56
0.5
1.53
2
1.2
0.5
0.75
0.75
Dividend per Share
3.29
3
3.4
1.13
1.99
2.67
2.71
7.11
13.47
15.18
15.44
16.92
20.83
- -
Book Value per Share
0.9
0.76
0.91
-4.93
-3.96
-5.31
-2.56
-1
-24.28
-28.49
-24.66
-21.59
-16.41
-20.46
Tangible Book Value per Share
91
91
77
79
102
100
111
112
119
122
122
122
122
122
Basic Weighted Avg Shares
906
984
1,057
1,562
2,333
2,482
3,479
5,273
7,993
9,084
9,685
10,286
10,442
10,442
Sales/Revenue/Turnover
10.77
10.64
10.34
6.49
6.86
6.41
5.42
10.46
11.94
7.84
4.51
6.96
7.94
7.45
Operating Margin (%)
30
25
22
44
88
99
233
274
478
723
919
812
809
- -
Depreciation Expense
74
78
80
78
120
129
141
518
719
480
190
252
560
337
Net Income, GAAP
23.77
23.54
23.65
22.36
23.67
18.16
21.94
21.14
22.22
19.77
43.36
37.28
27.2
33.53
Effective Tax Rate (%)
8.14
7.93
7.61
4.98
5.16
5.21
4.04
9.82
9
5.28
1.96
2.45
5.36
3.23
Profit Margin (%)
90
65
117
-41
-346
-477
-280
-53
-2,161
-884
-697
744
158
-278
Working Capital
25
32
- -
301
4
10
149
242
788
2,969
2,886
4,093
2,831
2,915
LT Debt
293
272
263
347
748
932
1,476
1,890
4,291
4,971
4,960
5,309
5,447
5,268
Total Equity
- -
25.38
27.88
13.81
11.31
8.38
7.05
16.99
13.26
5.99
2.37
4.35
5.83
4.97
Return on Invested Capital (%)
- -
25.04
27.67
19.14
19.29
14.61
12.8
37.57
20.78
8.61
4.71
6.12
9.76
6.43
Return on Capital (%)
- -
27.18
29.94
44.22
82.4
54.89
49.46
94.32
59.76
27.76
10.19
12.78
24.34
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
979
1,984
2,119
LT Borrowings
3,738
- -
- -
LT Finance Leases
355
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
122
122
122
Market Capitalization
56,869
51,596
48,653

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
3,929
3,747
3,818
Cash, Cash Equivalents & STI
331
368
253
Accounts Receivable, Net
1,531
1,727
1,846
Inventories
1,724
1,652
1,719
Total Current Liabilities
3,185
3,989
4,096
Payables & Accruals
- -
- -
- -
ST Debt
979
1,984
2,119
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
41.08%
30.45%
2.6%
Free Cash Flow
44.4%
11.6%
38.85%
Net Income, GAAP
43.59%
20.01%
122.22%
Sales/Revenue/Turnover
27.49%
15.91%
1.52%
Total Cash Common Dividend
44.31%
41.89%
49.18%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,570
2,554
2,344
2,818
10,286
2025
2,702
2,578
2,733
- -
10,442
2026
2,645
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.51
0.59
0.2
0.77
2.07
2025
0.98
0.82
2.13
- -
4.6
2026
1.04
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.5
- -
- -
0.5
2025
- -
0.75
- -
- -
0.75
2026
- -
- -
- -
- -
- -
Similar Companies
Improve Medical Instruments Co., Ltd. (300030.SZ)
Nephros, Inc. (NEPH)
Menicon Co Ltd (MECNY)
ReGen Biologics Inc. (RGBOQ)
Innovative Eyewear, Inc. (LUCY)
Zentek Ltd. (ZTEK)
Business
AddLife AB (publ) operates as an independent European player within the life science sector, supplying a diverse array of equipment, consumables, and reagents primarily to healthcare systems, research institutions, educational establishments, and the food and pharmaceutical industries. The company structures its operations across two distinct segments: Labtech and Medtech. The Labtech segment delivers products, comprehensive solutions, and services focused on diagnostics, biomedical research, and laboratory analysis, encompassing areas such as hematology, pathology, point-of-care diagnostics, cell biology, genetics, microbiology, molecular biology, clinical chemistry, immunology, and analytical instruments. This segment additionally offers extensive support, maintenance, consulting, and training services to its clientele. The Medtech segment is dedicated to providing medical device products for surgery, respiration, intensive care, wound care, enteral nutrition, and ear, nose, and throat procedures, alongside welfare technology, assistive devices for home care, and specialized aids for children with disabilities. AddLife has a significant presence across approximately 30 countries in Europe, including Sweden, Finland, Denmark, Norway, the United Kingdom, Ireland, Germany, Italy, Austria, Switzerland, and Spain. Recent strategic moves include the April 2025 acquisition of Edge Medical Ltd., enhancing its offerings in orthopedic surgery, and the July 2024 acquisition of BonsaiLab, which bolstered its molecular biology capabilities in the Iberian market. Founded in 1906, AddLife AB (publ) maintains its headquarters in Stockholm, Sweden.

Company News

APIChat

  • seekingalpha.com

    AddLife AB (publ) (ADDLF) Q1 2026 Earnings Call Transcript

  • seekingalpha.com

    AddLife AB (publ) (ADDLF) Q4 2025 Earnings Call Transcript